Highest-materiality recent filing
Passage Bio cuts ~75% of workforce, expects $3.3M in severance costs
Workforce reduction of approximately 75%; substantial completion expected in Q2 and Q3 2026.
PBFT02 patients with global CDR 1 at baseline showed 64% less whole brain atrophy (3.1% vs 8.7%) at 12 months vs ALLFTD natural history.
Passage Bio terminates Hopewell lease; pays $4.8M fee, cash runway to Q1 2027
Terminated 62,000 sq ft lab lease (15-year term from March 2021) via Termination Agreement dated March 4, 2026.
Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.
Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027
Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.
Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing
Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.
Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027
Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.
Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to mean 25.9 ng/mL at 12 months (n=4); Dose 2 patient rose to 7.6 ng/mL at 1 month.
Passage Bio Q1 2025 net loss $15.4M; cash runway into Q1 2027; first FTD-GRN patient dosed at Dose 2
Net loss of $15.4M ($0.25 per share) vs $16.7M ($0.30 per share) in Q1 2024.
Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.
Received Nasdaq deficiency notice on Aug 1, 2024 for bid price below $1.00 for 30 consecutive days.
Passage Bio cuts workforce 55%, extends cash runway into Q1 2027; updates PBFT02 data
Preliminary cash $76.8M as of Dec 31, 2024; expected runway into Q1 2027 after restructuring.
Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026
Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.
Capsid comparison in NHPs: AAV1 vector achieved superior human PGRN levels in CSF versus AAV5 and AAVhu68 after ICM administration.
PBFT02 shows robust CSF progranulin increase; well-tolerated with enhanced immunosuppression
CSF PGRN up to 6-fold at month 1 (10.7-17.3 ng/mL) and up to 10-fold at month 6 (21.7-27.3 ng/mL), exceeding healthy controls (3.3-8.2 ng/mL).
Passage Bio expects $3.5M-$5.5M impairment charge on sublease of lab space
Subleased 3,200 sq ft (5% of 62,000 sq ft lab) in Hopewell, NJ; term Sept 2024 to Sept 2029, option to extend to 2032.
Passage Bio reports Q2 net loss $16M; advances upliFT-D trial, out-licenses programs to GEMMABio
Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial; FDA agreed to expand trial to FTD-C9orf72 patients.
Passage Bio receives Nasdaq delisting notice for bid price below $1.00
Notice received Aug 1, 2024; closing bid price below $1.00 for 30 consecutive days.
Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.
Passage Bio gets FDA green light to add FTD-C9orf72 arm to PBFT02 trial
Positive Type C meeting feedback from FDA supports evaluating PBFT02 in FTD-C9orf72 patients.
Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients
Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.
On September 9, 2024, the board of directors (the “ Board ”) of Passage Bio, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Thomas Kassberg as a Class I director and as a member of the Audit Committee of the Board, effective as of September 10, 2024 (the “ Appointment Date ”).
On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.
Max materiality 0.90 · Median 0.65 · Most common event other_material